For example, even though serum prostate-specific antigen (PSA) has been routinely used for screening individuals [2,3], recent studies proposed prostate-specific membrane antigen (PSMA) as a more precise and specific test for PCa screening and prognosis [4]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.